Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIC: MP0317 plus chemoimmunotherapy in first-line advanced biliary tract carcinoma
2024-520029-35-01Phase 2Authorised
- Sponsor
- CHRU Nancy
- Start
- Sep 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MP0317 in biliary cancer and cholangiocarcinoma (CCA) (2 arms), sponsored by CHRU Nancy. Primary endpoint: Progression-free survival status at 12 months. Planned start Sep 2025; status: authorised.
02
Drugs
MP0317
03
Conditions
biliary cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2024-520029-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520029-35-01.